Dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsGwong-Jen J. Chang, Wayne D. Crill, Holly R. Hughes, Brent S. Davis
Life of this patent
Estimating the term…
Abstract
Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.
Claims13
An isolated cross-reactivity reduced dengue virus E-glycoprotein polypeptide, wherein the polypeptide is a dengue serotype 1 virus (DENV-1) E-glycoprotein polypeptide comprising an arginine at position 106, an aspartic acid at position 107, an aspartic acid at position 310, a lysine at position 311, a glutamine at position 364, an isoleucine at position 468, a threonine at position 478, a valine at position 482 and a leucine at position 487, numbered with reference to SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.